Vulvar adenocarcinoma
MONDO:0024336An adenocarcinoma that arises from the vulva. Representative examples include Bartholin gland adenocarcinoma, eccrine adenocarcinoma, apocrine adenocarcinoma, and sebaceous carcinoma.
Also known as: adenocarcinoma of the vulva, adenocarcinoma of vulva, mammalian vulva adenocarcinoma, vulva adenocarcinoma, vulvar adenocarcinoma
2853 clinical trials for this condition and its sub-types, 3 tagged with Vulvar adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Vulvar adenocarcinoma
-
Vulval Paget disease 2 trials
-
Bartholin gland adenocarcinoma 0 trials
1 sub-type
-
Adenocarcinoma of skene gland origin 0 trials
-
Vulvar apocrine adenocarcinoma 0 trials
-
Vulvar clear cell hidradenocarcinoma 0 trials
-
Vulvar eccrine adenocarcinoma 0 trials
1 sub-type
- Vulvar eccrine porocarcinoma 0 trials
-
Vulvar sebaceous carcinoma 0 trials
-
New smart chemo targets tumors, spares healthy tissue
Disease control Recruiting nowThis early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…
Phase 1 • Sponsor: Avacta Life Sciences Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug lorigerlimab takes on Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis phase 2 trial is testing a drug called lorigerlimab in about 80 people with advanced ovarian or clear cell gynecologic cancers that have stopped responding to platinum chemotherapy. Lorigerlimab is a bispecific antibody designed to activate the immune system against tumors. …
Phase 2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to fight Hard-to-Treat vulvar cancer
Disease control Recruiting nowThis Phase 2 trial is testing whether two drugs, pembrolizumab and lenvatinib, can shrink or control vulvar cancer that cannot be surgically removed. About 80 participants will receive the combination in 21-day cycles. The study will measure tumor response and track side effects.
Phase 2 • Sponsor: National Cancer Institute, Naples • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC